Head of Precision Diagnostics - US

Ibex Medical Analytics•Boston, MA

1d•Hybrid

About The Position

The Head of Precision Diagnostics will be a pivotal leader responsible for driving the growth of Ibex’s biopharma business by identifying, shaping, and securing high-value strategic partnerships. This role demands a rare blend of deep clinical credibility and sharp market strategy rooted in precision medicine. Acting as the intellectual engine of our Biopharma business, you will translate complex clinical needs into AI-driven solutions, map out high-potential pharma pipelines, and lead the scientific and strategic engagement. Utilizing your deep expertise in oncology biomarkers and companion diagnostics (CDx), you will align Ibex's capabilities with pharma drug development and commercialization needs. The ultimate measure of success for this role is accelerating pipeline velocity and successfully securing strategic partnerships and commercial deals with biopharma companies.

Requirements

Ph.D. or M.D. in Life Sciences, Oncology, Pathology, Molecular Diagnostics, or a highly related field is a strict requirement to command immediate clinical and scientific credibility with partners.
Minimum of 7+ years of experience in corporate strategy, scientific alliances, medical affairs, or strategic business development within the biopharma or precision medicine sectors.
Proven track record and deep, hands-on experience in oncology biomarker development and companion diagnostics (CDx). Must have a thorough understanding of how assays and biomarkers are integrated into clinical trials and drug development workflows.
Demonstrated ability to understand complex AI/digital pathology technology and translate it seamlessly into a high-value business case for pharma drug development.
Exceptional communication and presentation skills, with the ability to influence and persuade executive-level scientists, clinicians, and commercial leaders alike.
Willingness to travel as required to engage with partners and lead presence at industry events.

Nice To Haves

Familiarity or experience contributing to regulatory strategy and CDx approval pathways (e.g., FDA/EMA frameworks) is highly desirable.

Responsibilities

Drive the end-to-end strategic engagement process with biopharma, from identifying key stakeholders to translating clinical needs into structured opportunities, with the ultimate goal of securing commercial deals.
Systematically analyze the biopharma landscape, clinical trials, and drug pipelines to identify the assets, oncology targets, and companies that have the highest strategic need for Ibex’s AI precision diagnostic and biomarker capabilities.
Define and articulate scientifically robust use cases that demonstrate how Ibex’s AI accelerates oncology biomarker development, patient stratification, and companion diagnostic (CDx) strategies.
Position Ibex and its leadership as premier thought leaders in the AI precision diagnostics space by representing the company at major industry conferences, symposia, and digital platforms.
Directly engage with biopharma partners to deeply map their pain points, clinical workflow challenges, and biomarker discovery needs.
Formulate immediate, high-value offerings leveraging Ibex's existing AI assets while building structured business cases for these solutions.
Act as the internal strategic bridge for the biopharma segment; identify future technological requirements based on market gaps, translating them into actionable feedback for internal R&D teams to expand Ibex’s core capabilities.
Maintain an exhaustive, real-time understanding of the competitive landscape, ensuring Ibex’s offerings remain highly differentiated.
Partner closely with Ibex’s internal clinical and medical teams to build and drive a strategic roadmap of scientific publications. This involves identifying key data generation opportunities that validate the clinical utility of Ibex's AI solutions, effectively positioning the company as the premier clinical partner of choice for biopharma organizations.
Collaborate with internal regulatory teams to contribute to the overarching regulatory strategy for the biopharma business, specifically regarding companion diagnostic (CDx) development pathways.